Changes in heart rate in patients with type 2 diabetes mellitus after treatment with luseogliflozin: Subanalysis of placebo-controlled, double-blind clinical trials

Motoaki Sano; Shi Chen; Hisae Imazeki; Hidekazu Ochiai; Yutaka Seino

doi:10.1111/jdi.12726

Changes in heart rate in patients with type 2 diabetes mellitus after treatment with luseogliflozin: Subanalysis of placebo-controlled, double-blind clinical trials

Motoaki Sano, Shi Chen, Hisae Imazeki, Hidekazu Ochiai, Yutaka Seino

内科学(循環器)

研究成果: Letter › 査読

35 被引用数 (Scopus)

本文言語	English
ページ（範囲）	638-641
ページ数	4
ジャーナル	Journal of Diabetes Investigation
巻	9
号	3
DOI	https://doi.org/10.1111/jdi.12726
出版ステータス	Published - 2018 5月

ASJC Scopus subject areas

内科学
内分泌学、糖尿病および代謝内科学

UN SDG

この成果は、次の持続可能な開発目標に貢献しています

文献へのアクセス

10.1111/jdi.12726

他のファイルとリンク

引用スタイル

@article{96540b6b5c064755af879b0631d2ca78,

title = "Changes in heart rate in patients with type 2 diabetes mellitus after treatment with luseogliflozin: Subanalysis of placebo-controlled, double-blind clinical trials",

author = "Motoaki Sano and Shi Chen and Hisae Imazeki and Hidekazu Ochiai and Yutaka Seino",

note = "Funding Information: Boehringer Ingelheim Co., Ltd., Johnson & Johnson and Takeda Pharmaceutical Company Limited. YS also received clini cal commissioned/joint research grants from Nippon Boehringer Ingelheim Co., Ltd., Eli Lilly and Company, Taisho Toyama Pharmaceutical Co., Ltd., MSD K.K., Ono Pharmaceutical Co., Ltd., Novo Nordisk Pharma Ltd., and ARKRAY, Inc. MS received joint research grants from Taisho Toyama Pharmaceutical Co., Ltd. HI, HO and SC are employees of Taisho Pharmaceutical Co., Ltd.",

year = "2018",

month = may,

doi = "10.1111/jdi.12726",

language = "English",

volume = "9",

pages = "638--641",

journal = "Journal of Diabetes Investigation",

issn = "2040-1116",

publisher = "Blackwell Publishing Asia Pty Ltd",

number = "3",

}

TY - JOUR

T1 - Changes in heart rate in patients with type 2 diabetes mellitus after treatment with luseogliflozin

T2 - Subanalysis of placebo-controlled, double-blind clinical trials

AU - Sano, Motoaki

AU - Chen, Shi

AU - Imazeki, Hisae

AU - Ochiai, Hidekazu

AU - Seino, Yutaka

N1 - Funding Information: Boehringer Ingelheim Co., Ltd., Johnson & Johnson and Takeda Pharmaceutical Company Limited. YS also received clini cal commissioned/joint research grants from Nippon Boehringer Ingelheim Co., Ltd., Eli Lilly and Company, Taisho Toyama Pharmaceutical Co., Ltd., MSD K.K., Ono Pharmaceutical Co., Ltd., Novo Nordisk Pharma Ltd., and ARKRAY, Inc. MS received joint research grants from Taisho Toyama Pharmaceutical Co., Ltd. HI, HO and SC are employees of Taisho Pharmaceutical Co., Ltd.

PY - 2018/5

Y1 - 2018/5

UR - http://www.scopus.com/inward/record.url?scp=85044531581&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044531581&partnerID=8YFLogxK

U2 - 10.1111/jdi.12726

DO - 10.1111/jdi.12726

M3 - Letter

C2 - 29750107

AN - SCOPUS:85044531581

SN - 2040-1116

VL - 9

SP - 638

EP - 641

JO - Journal of Diabetes Investigation

JF - Journal of Diabetes Investigation

IS - 3

ER -